Marinus Pharmaceuticals, Inc. (MRNS)
- Previous Close
1.4200 - Open
1.4200 - Bid 1.3900 x 1600
- Ask 1.4200 x 1600
- Day's Range
1.3800 - 1.4550 - 52 Week Range
1.1100 - 11.2600 - Volume
1,129,892 - Avg. Volume
1,749,282 - Market Cap (intraday)
77.178M - Beta (5Y Monthly) 0.89
- PE Ratio (TTM)
-- - EPS (TTM)
-2.6300 - Earnings Date May 9, 2024 - May 13, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
8.80
Marinus Pharmaceuticals, Inc., a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings. The company's ZTALMY product candidate acts at synaptic and extrasynaptic GABAA receptors, a target for its anti-seizure, antidepressant, and anxiolytic potential. It is developing ganaxolone for treating genetic epilepsy disorders, such as PCDH19-related epilepsy, and tuberous sclerosis complex. Marinus Pharmaceuticals, Inc. has license agreement with Purdue Neuroscience Company and CyDex Pharmaceuticals, Inc.; and collaboration agreement with Orion Corporation and Tenacia Biotechnology (Shanghai) Co., Ltd. Marinus Pharmaceuticals, Inc. was incorporated in 2003 and is headquartered in Radnor, Pennsylvania.
marinuspharma.comRecent News: MRNS
Performance Overview: MRNS
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: MRNS
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: MRNS
Valuation Measures
Market Cap
77.18M
Enterprise Value
638.11k
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
2.44
Price/Book (mrq)
4.60
Enterprise Value/Revenue
0.02
Enterprise Value/EBITDA
-0.01
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-38.19%
Return on Equity (ttm)
-213.02%
Revenue (ttm)
30.99M
Net Income Avi to Common (ttm)
-141.4M
Diluted EPS (ttm)
-2.6300
Balance Sheet and Cash Flow
Total Cash (mrq)
150.29M
Total Debt/Equity (mrq)
658.26%
Levered Free Cash Flow (ttm)
-70.09M